JPWO2022244757A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022244757A5 JPWO2022244757A5 JP2023522667A JP2023522667A JPWO2022244757A5 JP WO2022244757 A5 JPWO2022244757 A5 JP WO2022244757A5 JP 2023522667 A JP2023522667 A JP 2023522667A JP 2023522667 A JP2023522667 A JP 2023522667A JP WO2022244757 A5 JPWO2022244757 A5 JP WO2022244757A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- superoxide dismutase
- pharmaceutical composition
- tumor
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000019197 Superoxide Dismutase Human genes 0.000 claims 20
- 108010012715 Superoxide dismutase Proteins 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 239000002246 antineoplastic agent Substances 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 7
- 208000033808 peripheral neuropathy Diseases 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 201000003120 testicular cancer Diseases 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 229940041181 antineoplastic drug Drugs 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- 208000021309 Germ cell tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000004454 Hyperalgesia Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 206010027452 Metastases to bone Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims 2
- 206010034299 Penile cancer Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 229940123237 Taxane Drugs 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 201000009036 biliary tract cancer Diseases 0.000 claims 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000012191 childhood neoplasm Diseases 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 201000002664 drug-induced hearing loss Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000010175 gallbladder cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000006359 hepatoblastoma Diseases 0.000 claims 2
- 208000029824 high grade glioma Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 2
- 208000030883 malignant astrocytoma Diseases 0.000 claims 2
- 201000011614 malignant glioma Diseases 0.000 claims 2
- 208000006178 malignant mesothelioma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000005282 malignant pleural mesothelioma Diseases 0.000 claims 2
- 208000025189 neoplasm of testis Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 201000008946 renal pelvis neoplasm Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000002314 small intestine cancer Diseases 0.000 claims 2
- 210000003594 spinal ganglia Anatomy 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 2
- 230000001573 trophoblastic effect Effects 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 208000024722 urethra neoplasm Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- ZSTCHQOKNUXHLZ-PIRIXANTSA-L [(1r,2r)-2-azanidylcyclohexyl]azanide;oxalate;pentyl n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate;platinum(4+) Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@@H]1CCCC[C@H]1[NH-].C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 ZSTCHQOKNUXHLZ-PIRIXANTSA-L 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000021731 hypoalgesia Diseases 0.000 claims 1
- 230000036032 hypoalgesia Effects 0.000 claims 1
- 208000034783 hypoesthesia Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000004126 nerve fiber Anatomy 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 210000002241 neurite Anatomy 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical group O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 230000008542 thermal sensitivity Effects 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021083610 | 2021-05-18 | ||
| JP2021083610 | 2021-05-18 | ||
| PCT/JP2022/020473 WO2022244757A1 (ja) | 2021-05-18 | 2022-05-17 | 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2022244757A1 JPWO2022244757A1 (https=) | 2022-11-24 |
| JPWO2022244757A5 true JPWO2022244757A5 (https=) | 2023-12-13 |
| JP7504367B2 JP7504367B2 (ja) | 2024-06-24 |
Family
ID=84141593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023522667A Active JP7504367B2 (ja) | 2021-05-18 | 2022-05-17 | 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240261375A1 (https=) |
| EP (1) | EP4353251A4 (https=) |
| JP (1) | JP7504367B2 (https=) |
| KR (1) | KR102843447B1 (https=) |
| CN (1) | CN117279657A (https=) |
| AU (1) | AU2022278242B2 (https=) |
| CA (1) | CA3220333A1 (https=) |
| CO (1) | CO2023017275A2 (https=) |
| MX (1) | MX2023013777A (https=) |
| TW (1) | TWI867299B (https=) |
| WO (1) | WO2022244757A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025178511A1 (ru) * | 2024-02-21 | 2025-08-28 | Евгений Владимирович ГРИГОРЬЕВ | Применение супероксиддисмутазы 2 в качестве антиоксиданта в сверхмалых дозировках |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0653670B2 (ja) * | 1985-10-28 | 1994-07-20 | 日研フ−ド株式会社 | 化学療法剤の副作用低減化剤 |
| JPH04135485A (ja) * | 1990-09-28 | 1992-05-08 | Seikagaku Kogyo Co Ltd | 白金錯体及び抗腫瘍剤 |
| JP3232542B2 (ja) | 1993-01-08 | 2001-11-26 | 宇部興産株式会社 | ヒトＣｕ，Ｚｎ型スーパーオキシドジスムターゼ誘導体及びその製造法 |
| JPH08208511A (ja) * | 1995-01-31 | 1996-08-13 | Samu Kenkyusho:Kk | 抗運動ニューロン疾患剤 |
| US6221848B1 (en) * | 1998-05-11 | 2001-04-24 | University Of Pittsburgh | Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy |
| US20020055467A1 (en) | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
| JP2001002585A (ja) * | 1999-06-22 | 2001-01-09 | Ltt Kenkyusho:Kk | レシチン化スーパーオキシドジスムターゼ含有抗線維化剤 |
| JP3792487B2 (ja) | 1999-06-24 | 2006-07-05 | 株式会社Ｌｔｔバイオファーマ | レシチン化スーパーオキシドジスムターゼ含有医薬組成物 |
| JP2003532691A (ja) | 2000-05-05 | 2003-11-05 | ノボ ノルディスク アクティーゼルスカブ | 重症疾患神経障害 |
| JP2002080395A (ja) * | 2000-08-31 | 2002-03-19 | Ltt Institute Co Ltd | 心筋傷害処置剤 |
| ES2375797T3 (es) | 2003-01-21 | 2012-03-06 | Genervon Biopharmaceuticals Llc | Péptidos y compuestos de factores tróficos de motoneuronas y sus procedimientos de utilización. |
| JP4958556B2 (ja) * | 2004-10-12 | 2012-06-20 | 株式会社Ｌｔｔバイオファーマ | レシチン化スーパーオキシドディスムターゼ組成物およびその製造方法 |
| WO2006050211A2 (en) | 2004-10-28 | 2006-05-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain |
| JP2006169128A (ja) | 2004-12-13 | 2006-06-29 | Ltt Bio-Pharma Co Ltd | 熱傷治療剤 |
| JP4867540B2 (ja) | 2006-09-20 | 2012-02-01 | 日本精工株式会社 | 無段変速装置 |
| US20100143321A1 (en) * | 2006-12-19 | 2010-06-10 | Ltt Bio Pharma Co., Ltd. | Therapeutic composition for interstitual pneumonia |
| JP5459827B2 (ja) | 2009-03-13 | 2014-04-02 | 株式会社Ｌｔｔバイオファーマ | 慢性閉塞性肺疾患改善剤 |
| EP2637698B1 (en) | 2010-11-09 | 2022-04-20 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| US9187509B2 (en) | 2012-01-05 | 2015-11-17 | Pled Pharma AB | Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment |
| JP6545926B2 (ja) * | 2012-11-30 | 2019-07-17 | 株式会社ナノエッグ | 手足症候群治療用組成物 |
| RU2017106172A (ru) | 2014-07-31 | 2018-08-28 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn) |
| EP2985036A3 (en) | 2014-08-14 | 2016-03-09 | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. | CYP2J2 antagonists in the treatment of pain |
| US11197862B2 (en) | 2015-07-16 | 2021-12-14 | Xomics Biopharma, Inc. | Methods of preventing toxicity of platinum drugs |
| JP6650612B2 (ja) | 2015-10-06 | 2020-02-19 | パナソニックＩｐマネジメント株式会社 | 照明制御装置及び照明システム |
-
2022
- 2022-05-17 CN CN202280033165.1A patent/CN117279657A/zh active Pending
- 2022-05-17 JP JP2023522667A patent/JP7504367B2/ja active Active
- 2022-05-17 US US18/560,442 patent/US20240261375A1/en active Pending
- 2022-05-17 EP EP22804668.6A patent/EP4353251A4/en active Pending
- 2022-05-17 CA CA3220333A patent/CA3220333A1/en active Pending
- 2022-05-17 WO PCT/JP2022/020473 patent/WO2022244757A1/ja not_active Ceased
- 2022-05-17 AU AU2022278242A patent/AU2022278242B2/en active Active
- 2022-05-17 MX MX2023013777A patent/MX2023013777A/es unknown
- 2022-05-17 KR KR1020237038088A patent/KR102843447B1/ko active Active
- 2022-05-18 TW TW111118516A patent/TWI867299B/zh active
-
2023
- 2023-12-14 CO CONC2023/0017275A patent/CO2023017275A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI641385B (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| JP2021504399A5 (https=) | ||
| KR20190011770A (ko) | 암 치료 | |
| CN101896227A (zh) | 包含mek抑制剂和极光激酶抑制剂的组合 | |
| JPWO2014157444A1 (ja) | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| KR20160064726A (ko) | 세포 투과 펩타이드-항암제 접합체 및 이를 포함하는 암 치료용 조성물 | |
| WO2017129094A1 (zh) | 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途 | |
| CN111909242A (zh) | 高亲和力特异性结合β-catenin蛋白的多肽及其应用和合成方法 | |
| JPWO2022244757A5 (https=) | ||
| US20160310605A1 (en) | Novel alkylating agent for alkylating target with driver oncogene mutation | |
| RU2010150964A (ru) | Произведенные из свр501 агенты и способы на их основе для ингибирования остановки клеточного цикла g2 и сенсибилизации клеток к повреждающим днк агентам | |
| CN109073650A (zh) | 包括对西地尼布进行固定的间歇给药的方法 | |
| EP2979701B1 (en) | Antitumor agent including irinotecan hydrochloride hydrate | |
| JP7504367B2 (ja) | 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物 | |
| RU2023133313A (ru) | Фармацевтическая композиция для лечения или профилактики расстройства, связанного с введением противоракового средства | |
| JP6458007B2 (ja) | 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
| Hoy | Trastuzumab Rezetecan: First Approval | |
| JP2025514724A (ja) | Ｄｄｘ５タンパク質に結合するカンプトセシン誘導体およびそのプロドラッグ | |
| CN1989112A (zh) | 癌症治疗方法 | |
| EP3541384A1 (en) | Treatment of cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype | |
| CN109481687B (zh) | 用于胃癌治疗的cdk4/6抑制剂联合her2抑制剂的组合 | |
| Coster et al. | 70P The human intratumor mycobiome is significantly influenced by an individual's race | |
| Kuai et al. | Mechanisms and relevant genes of drug resistance in gastric cancer | |
| Abrams et al. | INCREASED NOTCH SIGNALING AND LOSS OF GOBLET CELL DIFFERENTIATION WITH PROGRESSION FROM BARRETT'S ESOPHAGUS TO ESOPHAGEAL ADENOCARCINOMA: A BETRNET STUDY | |
| JP2015199677A (ja) | ノギテカン塩酸塩を含有する抗腫瘍剤及び抗腫瘍効果増強剤 |